| SOX2‐mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma L Hüser, S Sachindra, K Granados, A Federico, L Larribère, D Novak, ... International journal of cancer 143 (12), 3131-3142, 2018 | 61 | 2018 |
| Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target E Orouji, A Federico, L Larribère, D Novak, DB Lipka, Y Assenov, ... International journal of cancer 145 (12), 3462-3477, 2019 | 50 | 2019 |
| Mithramycin A and mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma A Federico, T Steinfass, L Larribère, D Novak, F Morís, LE Núñez, ... Molecular Therapy-Oncolytics 18, 83-99, 2020 | 29 | 2020 |
| T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells K Granados, L Hüser, A Federico, S Sachindra, G Wolff, T Hielscher, ... British journal of cancer 122 (7), 1023-1036, 2020 | 24 | 2020 |
| ATRT–SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance A Federico, C Thomas, K Miskiewicz, N Woltering, F Zin, K Nemes, ... Acta Neuropathologica 143 (6), 697-711, 2022 | 20 | 2022 |
| FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor Q Sun, D Novak, L Hüser, J Poelchen, H Wu, K Granados, A Federico, ... International journal of cancer 149 (3), 657-674, 2021 | 18 | 2021 |
| Defining the molecular features of radiation-induced glioma: a systematic review and meta-analysis JP Whitehouse, M Howlett, A Federico, M Kool, R Endersby, NG Gottardo Neuro-Oncology Advances 3 (1), vdab109, 2021 | 15 | 2021 |
| HER3-receptor-mediated STAT3 activation plays a central role in adaptive resistance toward vemurafenib in melanoma L Hüser, MM Kokkaleniou, K Granados, J Dworacek, A Federico, ... Cancers 12 (12), 3761, 2020 | 8 | 2020 |
| Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses K Okonechnikov, A Federico, D Schrimpf, P Sievers, F Sahm, J Koster, ... Acta neuropathologica communications 11 (1), 7, 2023 | 7 | 2023 |
| Atypical teratoid/rhabdoid tumor (AT/RT) with molecular features of pleomorphic xanthoastrocytoma C Thomas, A Federico, M Sill, S Bens, F Oyen, K Nemes, PD Johann, ... The American journal of surgical pathology 45 (9), 1228-1234, 2021 | 7 | 2021 |
| Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities I Paassen, J Williams, C Ríos Arceo, F Ringnalda, KS Mercer, JL Buhl, ... Oncogene 42 (20), 1661-1671, 2023 | 6 | 2023 |
| Low-grade diffusely infiltrative tumour (LGDIT), SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC M Hasselblatt, C Thomas, A Federico, S Bens, M Hellström, ... Neuropathology and Applied Neurobiology 48 (4), 2022 | 6 | 2022 |
| SMARCB1-deficient and SMARCA4-deficient malignant brain tumors with complex copy number alterations and TP53 mutations may represent the first clinical manifestation of li … M Hasselblatt, C Thomas, A Federico, K Nemes, PD Johann, B Bison, ... The American journal of surgical pathology 46 (9), 1277-1283, 2022 | 5 | 2022 |
| Secretogranin II influences the assembly and function of MHC class I in melanoma T Steinfass, J Poelchen, Q Sun, G Mastrogiulio, D Novak, M Vierthaler, ... Experimental hematology & oncology 12 (1), 29, 2023 | 4 | 2023 |
| Molecular and functional characterization of the role of the histone methyltransferase SETDB1 in malignant melanoma A Federico | 2 | 2020 |
| Patient‐and xenograft‐derived organoids recapitulate pediatric brain tumor features and patient treatments C Lago, A Federico, G Leva, NL Mack, B Schwalm, C Ballabio, ... EMBO molecular medicine 15 (12), e18199, 2023 | 1 | 2023 |
| Abstract A180: the histone methyltransferase SETDB1 contributes to melanoma tumorigenesis E Orouji, A Federico, L Larribere, D Novak, J Utikal Molecular Cancer Therapeutics 17 (1_Supplement), A180-A180, 2018 | 1 | 2018 |
| Diffuse infiltrating tumour with the molecular profile of an atypical teratoid rhabdoid tumour (AT/RT SHH-1B) in an adult patient F Cordier, JW Schouten, M Geurts, JM Kros, HJ Dubbink, V Verlinden, ... Neuropathology and applied neurobiology 50 (3), e12983, 2024 | | 2024 |
| ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models E Indersie, S Branchereau, B Fresneau, C Chardot, D Surdez, ... Cancer Research 84 (6_Supplement), 5469-5469, 2024 | | 2024 |
| Inhibition of PARP results in highly effective radiosensitization of Gr. 3 medulloblastomas S Feyerabend, N Köppen, T Rieckmann, B Riepen, A Oetting, ... Klinische Pädiatrie 235 (06), 2023 | | 2023 |
